Because specific pharmacological inhibitors for MLK4 are lacking, we had to select the first generation MLK inhibitor K252a and the newer class of more selective MLK inhibitor URMC-099 to examine the effect of these inhibitors on cancer cells. The gene discussed is MAP3K13; the disease is cancer.